Table 1. Patient, disease, and treatment characteristics (n = 102).
| Features | Median ± Standard Deviation/Percentage |
|---|---|
| Age | 51 ± 11 years |
| Initial Tumour Size | 5.2 ± 2.8 cm |
| Histology | |
| Invasive Ductal Carcinoma: 87% | |
| Invasive Lobular Carcinoma: 6% | |
| Other: 7% | |
| Tumour Grade | |
| Grade 1: 7% | |
| Grade 2: 43% | |
| Grade 3: 46% | |
| Unavailable: 4% | |
| Molecular Features | |
| HR+/HER2-: 41% | |
| HR+/HER2+: 20% | |
| HR-/HER2+: 14% | |
| Triple-negative: 25% | |
| Neoadjuvant chemotherapy | |
| AC-T (51%) | |
| FEC-D (41%) | |
| Others (8%) | |
| Residual Tumour Size | 1.9 ± 4.1 cm |
Abbreviations: HR: Hormone receptor; HER2: Human epidermal growth factor receptor 2; AC-T: doxorubicin and cyclophosphamide followed by paclitaxel; FEC-D: 5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel.